BioPharma Credit (LSE: BPCR)

Currency in USD

Last close As at 26/05/2023


0.00 (0.00%)

Market capitalisation


Latest Insights

View More

Investment Companies

BioPharma Credit – executive interview

Investment Companies

Biopharma Credit — New transaction of up to US$50m

Investment Companies

Biopharma Credit — Fully invested after recent transactions

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (0.2) (0.6) (3.4)
Relative (4.2) (9.7) (4.8)
52 week high/low US$1.0/US$0.9


BioPharma Credit (BPCR) is on track to deliver a strong (possibly record-high) annual NAV total return (TR) in FY22 on the back of a high investment level in H122, rising interest rates benefiting its floating rate loans, as well as healthy prepayment and make-whole fees from the early loan repayments in recent months. This has allowed BPCR to announce a US$0.045 special dividend, which implies a 12.0% dividend yield for FY22 on the current share price. The above-mentioned fees also provide BPCR with a good income runway for the re-deployment of prepayment proceeds. Since being fully invested in August 2018, BPCR achieved a net NAV TR of c 8% per year.



Investment Companies

European equities

Investment Companies

Listed Private Equity

Investment Companies

Vietnamese equities: Due a comeback?


IPO apocalypse

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free